Key Segments:
By Service Type
-
Preclinical Imaging and Biodistribution Studies
-
Dosimetry Studies
-
Bioanalytical and Safety Testing
-
Regulatory and Radiochemistry Support
By Radiopharmaceutical Type
-
Diagnostic Radiopharmaceuticals
-
Therapeutic/Radioligand Therapeutics
By Application
-
Oncology
-
Neurology
-
Cardiology
-
Other Applications
By End User
-
Pharmaceutical Companies
-
Biotechnology Companies
-
Academic and Research Institutes
Regional Coverage:
North America
-
US
-
Canada
-
Europe
-
Germany
-
France
-
UK
-
Italy
-
Spain
-
Poland
-
Russia
-
Rest of Europe
Asia Pacific
-
China
-
India
-
Japan
-
South Korea
-
Australia
-
ASEAN Countries
-
Rest of Asia Pacific
Middle East & Africa
-
UAE
-
Saudi Arabia
-
Qatar
-
South Africa
-
Rest of Middle East & Africa
Latin America
-
Brazil
-
Argentina
-
Mexico
-
Colombia
-
Rest of Latin America
Available Customization:
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
-
Detailed Volume Analysis
-
Criss-Cross segment analysis (e.g. Product X Application)
-
Competitive Product Benchmarking
-
Geographic Analysis
-
Additional countries in any of the regions
-
Customized Data Representation
-
Detailed analysis and profiling of additional market players
Frequently Asked Questions
The market is driven by an accelerating radioligand therapy pipeline, rising sponsor preference for outsourced imaging, dosimetry, and regulatory support, and expanding isotope supply chain investment.
The Diagnostic Radiopharmaceuticals segment dominated the Radiopharmaceutical CRO Market, accounting for approximately 61.50% share in 2025.
Key opportunities include expanding theranostic imaging-therapy pairing, rising targeted alpha emitter demand, and growing capacity investment across emerging nuclear medicine hubs in Asia Pacific.
Key players include Charles River Laboratories, Medpace, Pharmaron, Labcorp Drug Development, PAREXEL International, Curium Pharma, Eckert & Ziegler, and Nucleus RadioPharma, among others.
The North America region dominated the Radiopharmaceutical CRO Market in 2025 with approximately 38.90% revenue share.